EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor

Clara Hwang, Veda N. Giri, John C. Wilkinson, Casey Wright, Amanda S. Wilkinson, Kathleen A. Cooney, Colin S. Duckett

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase polycomb group (PcG) protein, which has been implicated in the process of cellular differentiation and cancer progression for both breast and prostate cancer. Although transcriptional repression by histone modification appears to contribute to the process of cellular differentiation, it is unclear what mediates the specificity of PcG proteins. Since EZH2 requires a binding partner for its histone methyltransferase activity, we surmised that evaluating interacting proteins might shed light on how the activity of EZH2 is regulated. Here we describe the identification of a novel binding partner of EZH2, the repressor of estrogen receptor activity (REA). REA functions as a transcriptional corepressor of the estrogen receptor and can potentiate the effect of anti-estrogens. REA expression levels have also previously been associated with the degree of differentiation of human breast cancers. We show here that EZH2 can also mediate the repression of estrogen-dependent transcription, and that moreover, the ability of both REA and EZH2 to repress estrogen-dependent transcription are mutually dependent. These data suggest that EZH2 may be recruited to specific target genes by its interaction with the estrogen receptor corepressor REA. The identification of a novel interaction between EZH2 and REA, two transcription factors that have been linked to breast cancer carcinogenesis, may lead to further insights into the process of deregulated gene expression in breast cancer.

Original languageEnglish (US)
Pages (from-to)235-242
Number of pages8
JournalBreast Cancer Research and Treatment
Volume107
Issue number2
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Co-Repressor Proteins
Estrogen Receptors
Estrogens
Genes
Polycomb-Group Proteins
Breast Neoplasms
Histone Code
Enhancer of Zeste Homolog 2 Protein
Prostatic Neoplasms
Carcinogenesis
Transcription Factors
Gene Expression

Keywords

  • Cancer
  • Estradiol
  • Estrogen receptor
  • Estrogen-dependent transcription
  • EZH2
  • REA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. / Hwang, Clara; Giri, Veda N.; Wilkinson, John C.; Wright, Casey; Wilkinson, Amanda S.; Cooney, Kathleen A.; Duckett, Colin S.

In: Breast Cancer Research and Treatment, Vol. 107, No. 2, 01.2008, p. 235-242.

Research output: Contribution to journalArticle

Hwang, Clara ; Giri, Veda N. ; Wilkinson, John C. ; Wright, Casey ; Wilkinson, Amanda S. ; Cooney, Kathleen A. ; Duckett, Colin S. / EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor. In: Breast Cancer Research and Treatment. 2008 ; Vol. 107, No. 2. pp. 235-242.
@article{6838c3a7d86c470886c7eb8494cf12d3,
title = "EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor",
abstract = "Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase polycomb group (PcG) protein, which has been implicated in the process of cellular differentiation and cancer progression for both breast and prostate cancer. Although transcriptional repression by histone modification appears to contribute to the process of cellular differentiation, it is unclear what mediates the specificity of PcG proteins. Since EZH2 requires a binding partner for its histone methyltransferase activity, we surmised that evaluating interacting proteins might shed light on how the activity of EZH2 is regulated. Here we describe the identification of a novel binding partner of EZH2, the repressor of estrogen receptor activity (REA). REA functions as a transcriptional corepressor of the estrogen receptor and can potentiate the effect of anti-estrogens. REA expression levels have also previously been associated with the degree of differentiation of human breast cancers. We show here that EZH2 can also mediate the repression of estrogen-dependent transcription, and that moreover, the ability of both REA and EZH2 to repress estrogen-dependent transcription are mutually dependent. These data suggest that EZH2 may be recruited to specific target genes by its interaction with the estrogen receptor corepressor REA. The identification of a novel interaction between EZH2 and REA, two transcription factors that have been linked to breast cancer carcinogenesis, may lead to further insights into the process of deregulated gene expression in breast cancer.",
keywords = "Cancer, Estradiol, Estrogen receptor, Estrogen-dependent transcription, EZH2, REA",
author = "Clara Hwang and Giri, {Veda N.} and Wilkinson, {John C.} and Casey Wright and Wilkinson, {Amanda S.} and Cooney, {Kathleen A.} and Duckett, {Colin S.}",
year = "2008",
month = "1",
doi = "10.1007/s10549-007-9542-7",
language = "English (US)",
volume = "107",
pages = "235--242",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor

AU - Hwang, Clara

AU - Giri, Veda N.

AU - Wilkinson, John C.

AU - Wright, Casey

AU - Wilkinson, Amanda S.

AU - Cooney, Kathleen A.

AU - Duckett, Colin S.

PY - 2008/1

Y1 - 2008/1

N2 - Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase polycomb group (PcG) protein, which has been implicated in the process of cellular differentiation and cancer progression for both breast and prostate cancer. Although transcriptional repression by histone modification appears to contribute to the process of cellular differentiation, it is unclear what mediates the specificity of PcG proteins. Since EZH2 requires a binding partner for its histone methyltransferase activity, we surmised that evaluating interacting proteins might shed light on how the activity of EZH2 is regulated. Here we describe the identification of a novel binding partner of EZH2, the repressor of estrogen receptor activity (REA). REA functions as a transcriptional corepressor of the estrogen receptor and can potentiate the effect of anti-estrogens. REA expression levels have also previously been associated with the degree of differentiation of human breast cancers. We show here that EZH2 can also mediate the repression of estrogen-dependent transcription, and that moreover, the ability of both REA and EZH2 to repress estrogen-dependent transcription are mutually dependent. These data suggest that EZH2 may be recruited to specific target genes by its interaction with the estrogen receptor corepressor REA. The identification of a novel interaction between EZH2 and REA, two transcription factors that have been linked to breast cancer carcinogenesis, may lead to further insights into the process of deregulated gene expression in breast cancer.

AB - Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase polycomb group (PcG) protein, which has been implicated in the process of cellular differentiation and cancer progression for both breast and prostate cancer. Although transcriptional repression by histone modification appears to contribute to the process of cellular differentiation, it is unclear what mediates the specificity of PcG proteins. Since EZH2 requires a binding partner for its histone methyltransferase activity, we surmised that evaluating interacting proteins might shed light on how the activity of EZH2 is regulated. Here we describe the identification of a novel binding partner of EZH2, the repressor of estrogen receptor activity (REA). REA functions as a transcriptional corepressor of the estrogen receptor and can potentiate the effect of anti-estrogens. REA expression levels have also previously been associated with the degree of differentiation of human breast cancers. We show here that EZH2 can also mediate the repression of estrogen-dependent transcription, and that moreover, the ability of both REA and EZH2 to repress estrogen-dependent transcription are mutually dependent. These data suggest that EZH2 may be recruited to specific target genes by its interaction with the estrogen receptor corepressor REA. The identification of a novel interaction between EZH2 and REA, two transcription factors that have been linked to breast cancer carcinogenesis, may lead to further insights into the process of deregulated gene expression in breast cancer.

KW - Cancer

KW - Estradiol

KW - Estrogen receptor

KW - Estrogen-dependent transcription

KW - EZH2

KW - REA

UR - http://www.scopus.com/inward/record.url?scp=37249011323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249011323&partnerID=8YFLogxK

U2 - 10.1007/s10549-007-9542-7

DO - 10.1007/s10549-007-9542-7

M3 - Article

C2 - 17453341

AN - SCOPUS:37249011323

VL - 107

SP - 235

EP - 242

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -